Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) continued in green a day later, after the company announced that the U.S. Supreme court has accepted to hear its appeal against NatcoPharma Ltd. (NTCPH) over patent revival that would enable the company to protect its drug, Copaxone multiple-sclerosis from generic competition. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares after opening at $54.39 moved to $54.62 on last trade day and at the end of the day closed at $53.00. Company price to sales ratio in past twelve months was calculated as 2.49 and price to cash ratio as 48.81.Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) showed a positive weekly performance of 7.18%.
Roth Capital hoisted their price objective on shares of Depomed (NASDAQ:DEPO) from $12.50 to $14.00 in a research note issued on Friday, American Banking and Market News reports. Roth Capital’s price objective would suggest a potential upside of 3.63% from the stock’s previous close. Depomed Inc (NASDAQ:DEPO) shares fell -2.22% in last trading session and ended the day on $13.21. DEPO return on equity ratio is recorded as 441.0% and its return on assets is 18.50%. Depomed Inc (NASDAQ:DEPO) yearly performance is 143.28%.
Lannett Company, Inc. (Lannett) announced that Arthur Bedrosian, President and CEO of Lannett, and Martin Galvan, CFO, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 5:00 p.m. ET at The Westin Grand Central Hotel, in New York. The Company added that an audio webcast of the presentation and its archive for 30 days will be available on its website. Lannett Company, Inc. (NYSE:LCI) shares moved down -7.26% in last trading session and was closed at $32.98, while trading in range of $32.05-$35.86.Lannett Company, Inc. (NYSE:LCI) year to date performance is -0.36%.
Orexigen Therapeutics, Inc. (Orexigen Therapeutics) announced its Q4 2013 and full-year 2013 financial results. Total revenues remained flat at $0.9 million and $3.4 million for Q4 2013 and full-year 2013, respectively. Net loss for Q4 2013 was $21.5 million or $0.21 per diluted share, compared to net loss of $32.5 million or $0.41 per diluted share in Q4 2012. Net loss for full year 2013 was $77.7 million or $0.80 per diluted share, compared to net loss of $90.1 million or $1.27 per diluted share in full year 2012. Orexigen Therapeutics, Inc. (NASDAQ:OREX) weekly performance is -6.46%. On last trading day company shares ended up $5.79.Orexigen Therapeutics, Inc. (NASDAQ:OREX) distance from 50-day simple moving average is -15.76%. Analysts mean target price for the company is $11.63.